Abbott and Bigfoot Biomedical have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott’s FreeStyle Libre glucose sensing technology with Bigfoot’s insulin delivery solutions. Under the agreement, Abbott will supply glucose measurement sensors for all of Bigfoot’s insulin delivery systems in the U.S. as the exclusive sensors for those systems. Bigfoot will develop and commercialize multiple systems using Abbott’s FreeStyle Libre sensor technology — including systems designed to perform auto-titration for Bigfoot’s connected insulin injection devices — as well as automated insulin delivery using Bigfoot’s insulin infusion platform. Bigfoot currently has both injection and infusion pump-based insulin delivery systems in development. The company expects to kickstart a trial incorporating FreeStyle Libre technology in 2018 at clinical research sites across the States.
News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal. We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. Go to the top of this page to sign up – we just need your email address.
